TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10393047

Group type: EXPERIMENTAL
Intervention: Acetazolamide (AZM) 500 mg/d
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8778430

Group type: EXPERIMENTAL
Intervention: 2.51 of fluid (1 l normal saline and 1.51 5% dextrose)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1 l of normal saline
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Free oral fluids
Number of subjects: 45
Study: 2055080

Group type: EXPERIMENTAL
Intervention: Lidocaine administration via instillation into the endotracheal tube (2 mg/kg, diluted to 10 mL)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lidocaine administration via bronchoscope deep endotracheally
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lidocaine administration via bronchoscope into the right main bronchus
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lidocaine administration via bronchoscope into the right lower lobe bronchus
Number of subjects: 32
Study: 6667814

Group type: EXPERIMENTAL
Intervention: Intravenous dl-carnitine infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 6
Study: 30076787

Group type: EXPERIMENTAL
Intervention: Dulaglutide once weekly
Number of subjects: 33

Group type: COMPARATOR
Intervention: Liraglutide once daily
Number of subjects: 33
Study: 29098323

Group type: EXPERIMENTAL
Intervention: Positive responses to the three questions from the Michigan Neuropathy Screening Instrument (MNSI)
Number of subjects: 8463

Group type: EXPERIMENTAL
Intervention: Positive responses to all three questions from the MNSI
Number of subjects: 8463

Group type: EXPERIMENTAL
Intervention: Addition of total number of affirmative responses to existing models
Number of subjects: 8463
Study: 26873695

Group type: EXPERIMENTAL
Intervention: Surgically modifiable factors (SMF)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Patient-specific factors (PSF)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both PSF and SMF
Number of subjects: 99
Study: 25240966

Group type: COMPARATOR
Intervention: Practice change intervention involving local leadership, electronic medical record modification, educational meetings, outreach, practice change resources, and performance monitoring.
Number of subjects: 1989

Group type: COMPARATOR
Intervention: Practice change intervention
Number of subjects: 1989
Study: 22340561

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 317

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study: 20628336

Group type: EXPERIMENTAL
Intervention: Platelet gels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Demineralized bone matrix
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthetic bone graft material (ceramics)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bone morphogenetic protein (rhBMP-2)
Number of subjects: 0
Study: 17681886

Group type: EXPERIMENTAL
Intervention: Submaximal isometric exercise (40% to 50% of max) for 2 minutes with the dominant hand
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (non-exercised hand)
Number of subjects: 14
Study: 16135728

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and colistin
Number of subjects: 47
Study: 11821455

Group type: EXPERIMENTAL
Intervention: Adjuvant cyclophosphamide, doxorubicin, and fluorouracil (CAF)
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Presence of a prominent plexiform vascular pattern
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Assessment of angiogenesis
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Angiogenesis measures
Number of subjects: 577
Study: 9809945

Group type: EXPERIMENTAL
Intervention: L-arginine (2 x 8 g/day)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (2 x 40 microg/day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (no hemodynamically active treatment)
Number of subjects: 39
Study: 7484753

Group type: EXPERIMENTAL
Intervention: rTPA therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Direct PTCA
Number of subjects: 42
Study: 2702795

Group type: EXPERIMENTAL
Intervention: Metoprolol (0.07 mg/kg) followed by isoproterenol (50 micrograms/min)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Metoprolol (0.07 mg/kg)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Isoproterenol sensitivity study
Number of subjects: 2
Study: 209263

Group type: EXPERIMENTAL
Intervention: Sucrose electrolyte solution
Number of subjects: 57

Group type: COMPARATOR
Intervention: Glucose electrolyte solution
Number of subjects: 57

Group type: COMPARATOR
Intervention: Intravenous hydration
Number of subjects: 57
Study: 31120173

Group type: COMPARATOR
Intervention: Topical anti-wrinkle cream (AM cream) only
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Topical anti-wrinkle cream (AM cream) and topical evening DNA repair serum (PM serum)
Number of subjects: 14
Study: 28533053

Group type: EXPERIMENTAL
Intervention: HIV vaccine trial participants (n = 51)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Ad5+ participants (n = 60)
Number of subjects: 111
Study: 26278124

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 10 mg weekly
Number of subjects: 52

Group type: COMPARATOR
Intervention: Corticosteroid OMP (dexamethasone 2.5 mg, 5 tablets taken on 2 consecutive days weekly)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups (MTX and OMP)
Number of subjects: 52
Study: 22825550

Group type: EXPERIMENTAL
Intervention: BCAA granules (nocturnal administration)
Number of subjects: 37

Group type: COMPARATOR
Intervention: BCAA granules (daytime administration)
Number of subjects: 37
Study: 21856481

Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil (intravenously for 2, 24, or 72 hours)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil (higher plasma concentrations)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil (high plasma concentrations)
Number of subjects: 45
Study: 19257913

Group type: EXPERIMENTAL
Intervention: Short-term enhanced infection control support
Number of subjects: 565

Group type: COMPARATOR
Intervention: Control group (no enhanced infection control support)
Number of subjects: 565
Study: 16702892

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 20 mg diazepam
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15364842

Group type: EXPERIMENTAL
Intervention: Mosaic (M) aortic valve replacement
Number of subjects: 100

Group type: COMPARATOR
Intervention: Perimount (P) aortic valve replacement
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both Mosaic and Perimount aortic valve replacements
Number of subjects: 100
Study: 11216075

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 6800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6800
Study: 9144042

Group type: EXPERIMENTAL
Intervention: Strontium-based toothpaste
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Potassium-based toothpaste
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fluoride toothpaste
Number of subjects: 120
Study: 8203688

Group type: EXPERIMENTAL
Intervention: Pediatric services plus early intervention services (intervention group)
Number of subjects: 985

Group type: COMPARATOR
Intervention: Pediatric follow-up and referral (follow-up only group)
Number of subjects: 985
Study: 3607576

Group type: EXPERIMENTAL
Intervention: Alizapride (14 mg/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Prochlorperazine (0.56 mg/kg)
Number of subjects: 32
Study: 31565828

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 28303751

Group type: EXPERIMENTAL
Intervention: Bevacizumab-containing treatment
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Increasing levels of all three peptides (n = 28)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Increasing levels of one or two peptides (n = 59)
Number of subjects: 97
Study: 25881090

Group type: EXPERIMENTAL
Intervention: Probiotics administered orally for 6 days preoperatively and 10 days postoperatively.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group received placebo orally for 6 days preoperatively and 10 days postoperatively.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Probiotics group.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 150
Study: 24078623

Group type: EXPERIMENTAL
Intervention: Postrelease planning for improving HIV medication adherence
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Postrelease planning for reducing sexual and injection drug-related transmission risk
Number of subjects: 162
Study: 21978943

Group type: EXPERIMENTAL
Intervention: Pulse oximetry
Number of subjects: 90

Group type: COMPARATOR
Intervention: Fetal electrocardiography (STAN® technology)
Number of subjects: 90
Study: 18816009

Group type: EXPERIMENTAL
Intervention: 6-week manualized guided self-help
Number of subjects: 102

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 102
Study: 16484823

Group type: EXPERIMENTAL
Intervention: PenV 1.5 million IU thrice daily for 20 days
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: PenV 1.5 million IU thrice daily for 14 days
Number of subjects: 102

Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 102
Study: 15006038

Group type: EXPERIMENTAL
Intervention: Patients with right frontal lobe lesions
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Patients with parietal lobe lesions
Number of subjects: 49

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 49
Study: 11345746

Group type: EXPERIMENTAL
Intervention: Milrinone (loading dose of 50 micrograms.kg‐1 and continuous infusion of 0.5 microgram.kg‐1.min‐1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (dopamine and nitroglycerine administered)
Number of subjects: 24
Study: 9152283

Group type: EXPERIMENTAL
Intervention: Playtex nipple unit
Number of subjects: 48

Group type: COMPARATOR
Intervention: Gerber NUK nipple
Number of subjects: 48

Group type: COMPARATOR
Intervention: Gerber Newborn nipple
Number of subjects: 48

Group type: COMPARATOR
Intervention: Evenflo nipple
Number of subjects: 48
Study: 8239591

Group type: EXPERIMENTAL
Intervention: Doxycycline plus rifampin (200 mg of doxycycline plus 600 mg of rifampin once daily for 6 weeks)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ofloxacin plus rifampin (400 mg of ofloxacin plus 600 mg of rifampin once daily for 6 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Doxycycline plus rifampin
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ofloxacin plus rifampin
Number of subjects: 61
Study: 3326117

Group type: EXPERIMENTAL
Intervention: 7.5 mg zopiclone
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5 mg nitrazepam
Number of subjects: 0
Study: 30382354

Group type: EXPERIMENTAL
Intervention: Betahistine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 27444427

Group type: EXPERIMENTAL
Intervention: Group BiT (Buried in Treasures)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Group CBT (Cognitive Behavioral Therapy)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Group BiT
Number of subjects: 300

Group type: COMPARATOR
Intervention: Group CBT
Number of subjects: 300
Study: 25039282

Group type: EXPERIMENTAL
Intervention: VR-CP (bortezomib 1.6 mg/m², rituximab 375 mg/m², cyclophosphamide 1000 mg/m², prednisone 100 mg)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: VR-CAP (bortezomib, rituximab, cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², prednisone)
Number of subjects: 55
Study: 22200806

Group type: EXPERIMENTAL
Intervention: Pamidronate (60 mg over 4 h in 500 ml of normal saline) administered monthly for 6 months
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 87
Study: 19879973

Group type: EXPERIMENTAL
Intervention: Sodium chenodeoxycholate (CDC) 500 mg or 1000 mg, given for 4 days
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Colesevelam (1.875 g, twice daily)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 18052925

Group type: EXPERIMENTAL
Intervention: Fish oil meal (31 g of mixed fat and 9 g of fish oil)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo oil meal (40 g of mixed fat)
Number of subjects: 25
Study: 12587957

Group type: EXPERIMENTAL
Intervention: Colon-targeted tablet-20
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Colon-targeted tablet-30
Number of subjects: 15

Group type: COMPARATOR
Intervention: Immediate release capsules
Number of subjects: 15
Study: 9598887

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) 1 mg/kg/day for 6 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 7753719

Group type: EXPERIMENTAL
Intervention: Written only format
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Written and verbal format
Number of subjects: 113
Study: 3140561

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 6017282

Group type: EXPERIMENTAL
Intervention: Double layer leucocyte agglutination method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-specific agglutination at 37°
Number of subjects: 0
Study: 31279680

Group type: EXPERIMENTAL
Intervention: Prognostic model for 18-month mortality after left-sided pancreatectomy
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Prognostic model validation
Number of subjects: 54
Study: 29129174

Group type: EXPERIMENTAL
Intervention: High concentration oxygen therapy (delivered via Hudson mask at 8 L/min, without regard to Spo2)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Titrated oxygen therapy (oxygen delivered via nasal prongs to achieve peripheral oxygen saturation [Spo2] of 88‐92%)
Number of subjects: 22
Study: 25741028

Group type: EXPERIMENTAL
Intervention: Previous simulation training (n=10)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No previous training (n=12)
Number of subjects: 22
Study: 23179204

Group type: EXPERIMENTAL
Intervention: C→H (cold to hot)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: H→C (hot to cold)
Number of subjects: 9
Study: 21470671

Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 7021

Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 7021
Study: 19232907

Group type: EXPERIMENTAL
Intervention: FX06
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 17013922

Group type: EXPERIMENTAL
Intervention: Piribedil (150-300 mg/day)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Piribedil
Number of subjects: 405
Study: 15233676

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.i.d.
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Tegaserod 12 mg b.i.d.
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Tegaserod (both doses)
Number of subjects: 53
Study: 11094181

Group type: EXPERIMENTAL
Intervention: Normal tension glaucoma (NTG)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Primary open-angle glaucoma (POAG)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Ocular hypertension (OH)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 79
Study: 9296407

Group type: EXPERIMENTAL
Intervention: 12.5 mg I.V. dolasetron
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: 25 mg I.V. dolasetron
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: 50 mg I.V. dolasetron
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: 100 mg I.V. dolasetron
Number of subjects: 620

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 620
Study: 8363066

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Epidural Anesthesia (EA)
Number of subjects: 100
Study: 31781732

Group type: EXPERIMENTAL
Intervention: High-Intensity Functional Exercise (HIFE) Program, 5 sessions per 2-week period for 4 months (total 40 sessions)
Number of subjects: 81
Study: 30361335

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (hemoglobin A1c <6.0%)
Number of subjects: 10251

Group type: COMPARATOR
Intervention: Standard therapy (control for glycemic control)
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Intensive BP control (systolic BP <120 mm Hg)
Number of subjects: 10251

Group type: COMPARATOR
Intervention: Standard therapy (control for BP control)
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 10251

Group type: COMPARATOR
Intervention: Placebo (control for fenofibrate)
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Intensive BP control
Number of subjects: 10251
Study: 27538108

Group type: EXPERIMENTAL
Intervention: Skin needling plus silicone gel (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Skin needling (Control for Group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Silicone gel plus skin needling (Group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Silicone gel (Control for Group B)
Number of subjects: 20
Study: 25066510

Group type: EXPERIMENTAL
Intervention: Study-defined delirium
Number of subjects: 2197

Group type: EXPERIMENTAL
Intervention: Study-defined subsyndromal delirium
Number of subjects: 2197

Group type: EXPERIMENTAL
Intervention: Age-specific prevalence of delirium
Number of subjects: 2197

Group type: EXPERIMENTAL
Intervention: Age-specific prevalence of subsyndromal delirium
Number of subjects: 2197
Study: 22070630

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway Unique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Laryngeal mask airway Supreme
Number of subjects: 50
Study: 19880501

Group type: EXPERIMENTAL
Intervention: Thalidomide 200 mg orally, days 1 to 28 plus adriamycin and dexamethasone
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Thalidomide 50 mg daily (maintenance)
Number of subjects: 556
Study: 17675321

Group type: EXPERIMENTAL
Intervention: 5 mg nebulised rhDNase
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Overall asthma score
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Oxygen supplementation and bronchodilator treatments
Number of subjects: 121
Study: 17142512

Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza vaccine-trivalent
Number of subjects: 1616
Study: 12576620

Group type: EXPERIMENTAL
Intervention: Erythromycin treatment for chancroid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single dose regimens for H ducreyi infection
Number of subjects: 0
Study: 11020674

Group type: EXPERIMENTAL
Intervention: Hoffmann reflex intervention
Number of subjects: 0
Study: 8678100

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 2032

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 2032

Group type: EXPERIMENTAL
Intervention: Cefepime high-dose
Number of subjects: 2032
Study: 1345436

Group type: EXPERIMENTAL
Intervention: Neo-EEG
Number of subjects: 115

Group type: COMPARATOR
Intervention: Conventional EEG
Number of subjects: 115
Study: 4008115

Group type: EXPERIMENTAL
Intervention: 1 mg ketotifen + 300 mg theophylline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1 mg ketotifen + 600 mg theophylline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1 mg ketotifen
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 300 mg theophylline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 600 mg theophylline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30690785

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 48
Study: 29474361

Group type: EXPERIMENTAL
Intervention: Fermented whey product
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 25986540

Group type: EXPERIMENTAL
Intervention: Liverpool Care Pathway for the Dying Patient
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 19
Study: 24283778

Group type: EXPERIMENTAL
Intervention: Glycopyrronium + Indacaterol (QVA149)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tiotropium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glycopyrronium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indacaterol
Number of subjects: 0
Study: 22946072

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy‐based guided self‐management intervention adapted for Maori
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 16
Study: 20142594

Group type: EXPERIMENTAL
Intervention: Brief educational session plus a CD‐ROM (n = 108)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Brief educational session with a health educator (n = 105)
Number of subjects: 213
Study: 17377957

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 73
Study: 15754228

Group type: EXPERIMENTAL
Intervention: Visual assessment of knee flexion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Goniometric assessment of knee flexion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Visual assessment of knee extension
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Goniometric assessment of knee extension
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Goniometric assessment of knee flexion (interobserver)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Visual assessment of knee flexion (interobserver)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Visual assessment of knee extension (interobserver)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Goniometric assessment of knee extension (interobserver)
Number of subjects: 30
Study: 12005116

Group type: COMPARATOR
Intervention: Sodium lauryl sulphate (SLS) 0.25% and 0.5% patch test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium lauryl sulphate (SLS) patch test
Number of subjects: 0
Study: 10459543

Group type: EXPERIMENTAL
Intervention: MMF 2g
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: MMF 3g
Number of subjects: 491

Group type: COMPARATOR
Intervention: PLA
Number of subjects: 491

Group type: COMPARATOR
Intervention: MMF 2g vs PLA
Number of subjects: 491

Group type: COMPARATOR
Intervention: MMF 3g vs PLA
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: PLA, MMF 2g, MMF 3g
Number of subjects: 491